Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: Aug 25, 2025 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K |
| Filed Date | Aug 25, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Catalyst Pharma filed an 8-K on 8/25/25 with corporate updates.
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on August 25, 2025, reporting on other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). It also lists its principal executive offices in Coral Gables, Florida.
Why It Matters
This 8-K filing provides an update on Catalyst Pharmaceuticals' corporate information and financial reporting, which is important for investors to stay informed about the company's structure and operational details.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.
Key Numbers
- 001-33057 — Commission File Number (Identifies the company's SEC filing history.)
- 76-0837053 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- August 25, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- Coral Gables, Florida (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily to report on 'Other Events' and 'Financial Statements and Exhibits' for Catalyst Pharmaceuticals, Inc.
When was this 8-K report filed?
The report was filed on August 25, 2025.
In which state is Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of Catalyst Pharmaceuticals' principal executive offices?
The principal executive offices are located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.
What is Catalyst Pharmaceuticals' fiscal year end?
The company's fiscal year ends on December 31.
Filing Stats: 636 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-08-25 16:30:16
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPR
Filing Documents
- d915025d8k.htm (8-K) — 26KB
- d915025dex991.htm (EX-99.1) — 8KB
- 0001193125-25-187733.txt ( ) — 149KB
- cprx-20250825.xsd (EX-101.SCH) — 3KB
- cprx-20250825_lab.xml (EX-101.LAB) — 18KB
- cprx-20250825_pre.xml (EX-101.PRE) — 11KB
- d915025d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on August 25, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: August 25, 2025 3